Level Biotechnology Valuation
| 3118 Stock | TWD 33.45 0.35 1.06% |
At this time, the firm appears to be fairly valued. Level Biotechnology secures a last-minute Real Value of NT$32.68 per share. The latest price of the firm is NT$33.45. Our model forecasts the value of Level Biotechnology from analyzing the firm fundamentals such as Profit Margin of 0.10 %, return on equity of 0.11, and Current Valuation of 489.43 M as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Level Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of Level Biotechnology is based on 3 months time horizon. Increasing Level Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Level stock is determined by what a typical buyer is willing to pay for full or partial control of Level Biotechnology. Since Level Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Level Stock. However, Level Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 33.45 | Real 32.68 | Hype 33.45 | Naive 33.66 |
The intrinsic value of Level Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Level Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Level Biotechnology helps investors to forecast how Level stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Level Biotechnology more accurately as focusing exclusively on Level Biotechnology's fundamentals will not take into account other important factors: Level Biotechnology Total Value Analysis
Level Biotechnology is presently anticipated to have takeover price of 489.43 M with market capitalization of 928.15 M, debt of 18.11 M, and cash on hands of 295.07 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Level Biotechnology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
489.43 M | 928.15 M | 18.11 M | 295.07 M |
Level Biotechnology Investor Information
About 32.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.71. In the past many companies with similar price-to-book ratios have beat the market. Level Biotechnology last dividend was issued on the 17th of June 2022. The entity had 1:1 split on the 5th of August 2011. Based on the key measurements obtained from Level Biotechnology's financial statements, Level Biotechnology is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Level Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Level Biotechnology has an asset utilization ratio of 85.99 percent. This indicates that the Company is making NT$0.86 for each dollar of assets. An increasing asset utilization means that Level Biotechnology is more efficient with each dollar of assets it utilizes for everyday operations.Level Biotechnology Ownership Allocation
Level Biotechnology maintains a total of 32.45 Million outstanding shares. Level Biotechnology holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Level Biotechnology Profitability Analysis
The company reported the revenue of 677.28 M. Net Income was 68.18 M with profit before overhead, payroll, taxes, and interest of 232.5 M.About Level Biotechnology Valuation
Our relative valuation model uses a comparative analysis of Level Biotechnology. We calculate exposure to Level Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Level Biotechnology's related companies.Level Biotechnology Inc. markets and distributes cell culture, immunology, molecular biology products and biomedical precision equipment in Taiwan. The company was founded in 1989 and is headquartered in New Taipei City, Taiwan. LEVEL BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 122 people.
8 Steps to conduct Level Biotechnology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Level Biotechnology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Level Biotechnology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Level Biotechnology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Level Biotechnology's revenue streams: Identify Level Biotechnology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Level Biotechnology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Level Biotechnology's growth potential: Evaluate Level Biotechnology's management, business model, and growth potential.
- Determine Level Biotechnology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Level Biotechnology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Level Stock Analysis
When running Level Biotechnology's price analysis, check to measure Level Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Level Biotechnology is operating at the current time. Most of Level Biotechnology's value examination focuses on studying past and present price action to predict the probability of Level Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Level Biotechnology's price. Additionally, you may evaluate how the addition of Level Biotechnology to your portfolios can decrease your overall portfolio volatility.